Work With Data
search
Profile
user
live In the news:
Lost it on Wegovy? You might gain it all back in a year / CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans / Novo Nordisk partners with Ro, Hims and LifeMD to sell low-cost Wegovy / Trump scraps Biden's plan to cover Wegovy and Zepbound through Medicare / Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundup / Wegovy sales took a hit this year. Novo's CEO blames off-brand competition / Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup / Novo Nordisk cuts Wegovy prices after similar move by Zepbound maker Eli Lilly / Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Wegovy

Updated: 34d ago

Wegovy is a company. It is a private company in the United States. It is part of the Health Care sector.

Key facts

  • country: United States
  • employees: 40 people
  • revenues: 4M $
  • company type: private
  • sector: Health Care
  • ESG score: 76.95 / 100
plus See more facts
link Website

Extract data

Download datasets about Wegovy:

dataset Dataset of stocks from Wegovy:

Wegovy is one of the companies in the United States, companies in Health Care and 3,456,808 companies in our database.

Talking Points

  • Prescription Weight Loss Medication | Wegovy® (semaglutide) Injection 2.4 mg
  • Learn how Wegovy® (semaglutide) can help adults with obesity or excess weight with weight related conditions. Read Important Safety and Prescribing Info, including Boxed Warning.

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.